ID: ALA606175

Max Phase: Preclinical

Molecular Formula: C33H34N2O2

Molecular Weight: 490.65

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(C(c2ccccc2)N2CCN(C(=O)CC(c3ccccc3)c3ccccc3)CC2)cc1

Standard InChI:  InChI=1S/C33H34N2O2/c1-37-30-19-17-29(18-20-30)33(28-15-9-4-10-16-28)35-23-21-34(22-24-35)32(36)25-31(26-11-5-2-6-12-26)27-13-7-3-8-14-27/h2-20,31,33H,21-25H2,1H3

Standard InChI Key:  HWGMUVSZGFXYSD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 490.65

Molecular Weight (Monoisotopic): 490.2620

AlogP: 6.15

#Rotatable Bonds: 8

Polar Surface Area: 32.78

Molecular Species: NEUTRAL

HBA: 3

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 6.90

CX LogP: 6.31

CX LogD: 6.19

Aromatic Rings: 4

Heavy Atoms: 37

QED Weighted: 0.30

Np Likeness Score: -0.76

References

1. Pajouhesh H, Feng ZP, Ding Y, Zhang L, Pajouhesh H, Morrison JL, Belardetti F, Tringham E, Simonson E, Vanderah TW, Porreca F, Zamponi GW, Mitscher LA, Snutch TP..  (2010)  Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors.,  20  (4): [PMID:20117000] [10.1016/j.bmcl.2010.01.008]

2.  (2004)  Calcium channel inhibitors comprising benzhydril spaced from piperazine, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data